Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a buy rating to a hold rating in a research note released on Thursday.

AMPH has been the topic of a number of other reports. Needham & Company LLC reissued a hold rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an overweight rating on the stock in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of Hold and an average price target of $63.00.

Amphastar Pharmaceuticals Trading Up 2.8 %

Amphastar Pharmaceuticals stock opened at $47.57 on Thursday. The stock has a 50-day moving average of $46.38 and a two-hundred day moving average of $42.95. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. Amphastar Pharmaceuticals has a one year low of $36.56 and a one year high of $65.92. The stock has a market cap of $2.33 billion, a PE ratio of 16.46, a price-to-earnings-growth ratio of 0.88 and a beta of 0.83.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.10. The business had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. On average, research analysts anticipate that Amphastar Pharmaceuticals will post 3.71 EPS for the current fiscal year.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total value of $139,410.00. Following the sale, the director now directly owns 75,409 shares of the company’s stock, valued at approximately $3,504,256.23. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Richard K. Prins sold 17,101 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the transaction, the director now owns 33,971 shares in the company, valued at $1,463,130.97. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now owns 75,409 shares of the company’s stock, valued at approximately $3,504,256.23. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,383 shares of company stock valued at $1,524,123 over the last ninety days. Company insiders own 27.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC raised its position in shares of Amphastar Pharmaceuticals by 70.0% during the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $1,710,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Amphastar Pharmaceuticals in the 2nd quarter valued at about $364,000. Cim LLC raised its holdings in Amphastar Pharmaceuticals by 7.5% in the 2nd quarter. Cim LLC now owns 10,016 shares of the company’s stock valued at $401,000 after acquiring an additional 701 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in Amphastar Pharmaceuticals in the 2nd quarter valued at about $388,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.